Skip to main content
Top
Published in: Diabetologia 1/2014

01-01-2014 | Letter

Nitric oxide vs insulin secretion, action and clearance

Author: Olga Kruszelnicka

Published in: Diabetologia | Issue 1/2014

Login to get access

Excerpt

To the Editor: In their Diabetologia article, Natali and colleagues [1] reported a decrease in glucose tolerance in response to acute inhibition of NO generation by N G-nitro-l-arginine methylester (L-NAME), which resulted from a 40% drop in beta cell glucose sensitivity and doubled insulin clearance, whereas peripheral insulin sensitivity did not change. Admittedly, whether conclusions from an acute experiment can apply to a long-term impairment of NO bioavailability remains disputable. Moreover, mice with genetic disruption of endothelial NO synthase, used as a model of chronic NO deficiency, exhibit insulin resistance (IR) in the liver and peripheral tissues [2]. Nevertheless, it can be speculated that depressed insulin secretion and enhanced insulin degradation, when superimposed on concomitant IR, might further impair glucose tolerance and accelerate the development of type 2 diabetes mellitus under conditions associated with reduced NO bioavailability. …
Literature
1.
go back to reference Natali A, Ribeiro R, Baldi S et al (2013) Systemic inhibition of nitric oxide synthesis in non-diabetic individuals produces a significant deterioration in glucose tolerance by increasing insulin clearance and inhibiting insulin secretion. Diabetologia 56:1183–1191PubMedCrossRef Natali A, Ribeiro R, Baldi S et al (2013) Systemic inhibition of nitric oxide synthesis in non-diabetic individuals produces a significant deterioration in glucose tolerance by increasing insulin clearance and inhibiting insulin secretion. Diabetologia 56:1183–1191PubMedCrossRef
2.
go back to reference Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD (2000) Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 49:684–687PubMedCrossRef Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD (2000) Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 49:684–687PubMedCrossRef
3.
go back to reference Meigs JB, Hu FB, Rifai N, Manson JE (2004) Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 291:1978–1986PubMedCrossRef Meigs JB, Hu FB, Rifai N, Manson JE (2004) Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 291:1978–1986PubMedCrossRef
4.
go back to reference Perticone F, Maio R, Sciacqua A et al (2008) Endothelial dysfunction and C-reactive protein are risk factors for diabetes in essential hypertension. Diabetes 57:167–171PubMedCrossRef Perticone F, Maio R, Sciacqua A et al (2008) Endothelial dysfunction and C-reactive protein are risk factors for diabetes in essential hypertension. Diabetes 57:167–171PubMedCrossRef
5.
go back to reference Mittermayer F, Kautzky-Willer A, Winzer C et al (2007) Elevated concentrations of asymmetric dimethylarginine are associated with deterioration of glucose tolerance in women with previous gestational diabetes mellitus. J Intern Med 261:392–398PubMedCrossRef Mittermayer F, Kautzky-Willer A, Winzer C et al (2007) Elevated concentrations of asymmetric dimethylarginine are associated with deterioration of glucose tolerance in women with previous gestational diabetes mellitus. J Intern Med 261:392–398PubMedCrossRef
6.
go back to reference Surdacki A, Kruszelnicka O, Rakowski T, Jaźwińska-Kozuba A, Dubiel JS (2013) Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study. Cardiovasc Diabetol 12:64PubMedCrossRef Surdacki A, Kruszelnicka O, Rakowski T, Jaźwińska-Kozuba A, Dubiel JS (2013) Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study. Cardiovasc Diabetol 12:64PubMedCrossRef
7.
8.
go back to reference Cordes CM, Bennett RG, Siford GL, Hamel FG (2009) Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation. Biochem Pharmacol 77:1064–1073PubMedCrossRef Cordes CM, Bennett RG, Siford GL, Hamel FG (2009) Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation. Biochem Pharmacol 77:1064–1073PubMedCrossRef
9.
go back to reference Wiseman DA, Thurmond DC (2012) The good and bad effects of cysteine S-nitrosylation and tyrosine nitration upon insulin exocytosis: a balancing act. Curr Diabetes Rev 8:303–315PubMedCrossRef Wiseman DA, Thurmond DC (2012) The good and bad effects of cysteine S-nitrosylation and tyrosine nitration upon insulin exocytosis: a balancing act. Curr Diabetes Rev 8:303–315PubMedCrossRef
10.
go back to reference Forrester MT, Seth D, Hausladen A et al (2009) Thioredoxin-interacting protein (Txnip) is a feedback regulator of S-nitrosylation. J Biol Chem 284:36160–36166PubMedCrossRef Forrester MT, Seth D, Hausladen A et al (2009) Thioredoxin-interacting protein (Txnip) is a feedback regulator of S-nitrosylation. J Biol Chem 284:36160–36166PubMedCrossRef
11.
go back to reference Shaked M, Ketzinel-Gilad M, Ariav Y, Cerasi E, Kaiser N, Leibowitz G (2009) Insulin counteracts glucotoxic effects by suppressing thioredoxin-interacting protein production in INS-1E beta cells and in Psammomys obesus pancreatic islets. Diabetologia 52:636–644PubMedCrossRef Shaked M, Ketzinel-Gilad M, Ariav Y, Cerasi E, Kaiser N, Leibowitz G (2009) Insulin counteracts glucotoxic effects by suppressing thioredoxin-interacting protein production in INS-1E beta cells and in Psammomys obesus pancreatic islets. Diabetologia 52:636–644PubMedCrossRef
12.
go back to reference Wang H, Wang AX, Aylor K, Barrett EJ (2013) Nitric oxide directly promotes vascular endothelial insulin transport. Diabetes. doi:10.2337/db13-0627 Wang H, Wang AX, Aylor K, Barrett EJ (2013) Nitric oxide directly promotes vascular endothelial insulin transport. Diabetes. doi:10.​2337/​db13-0627
Metadata
Title
Nitric oxide vs insulin secretion, action and clearance
Author
Olga Kruszelnicka
Publication date
01-01-2014
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 1/2014
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-013-3082-y

Other articles of this Issue 1/2014

Diabetologia 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.